Jan 23 2013 | 8:53 AM

Fourth Belgian Equity Investments Conference

NYSE Euronext hosted the fourth Belgian Equity Investments Conference at the New York Stock Exchange on 19 November. Marc Calcoen, Consul General of Belgium in New York, Philippe Ledent, Senior Economist at ING, and executives of leading listed Belgian companies rang the NYSE Opening Bell, together with Vincent Van Dessel, Chairman and CEO of NYSE Euronext in Brussels.

The event, sponsored by ING and NYSE Euronext, provided an opportunity for leading NYSE Euronext-listed companies headquartered in Belgium to address the U.S. and global investor community directly. 

First corporate bond seminar


NYSE Euronext in Brussels organized its first...

Lees Meer
Jan 23 2013 | 8:48 AM

4th Edition of Portuguese Day in New York

NYSE Euronext and Caixa-BI welcomed 15 listed companies for an investor road show in New York on 15 and 16 October. Mr Carlos Moedas, Secretary of the State to the Portuguese Prime Minister, and João Moreira Rato, CEO of Portuguese debt agency IGCP, accompanied the delegation to New York. Participating companies met with around 90 investors during 260 meetings over the course of the two days.

Strong headwinds from the Portuguese economy did not frighten the attending companies or investors. The mood overall was very positive. Investors were more interested to hear about companies’ fundamentals than about the economy itself, which might not have been the case a few months ago.

2012 Bell Ceremonies

In 2012, NYSE Euronext welcomed listed companies, leaders in business and politics, and...

Lees Meer
Jan 23 2013 | 8:46 AM

“The stock exchange helps accelerate Nanobiotix’s development”

Nanobiotix entered Compartment C of NYSE Euronext in Paris on 29 October allowing the company to raise €14.2 million to pursue the clinical development of its revolutionary technology. Interview with CEO Laurent Lévy.

Could you briefly describe Nanobiotix?

We are a nanomedical company specialized in cancer treatment. Our area of intervention is radiation therapy, a technique used with nearly 60% of patients today and which has proven very effective in eliminating cancerous cells. However, it has the significant drawback of also destroying the healthy tissue surrounding cancer cells. The nanoparticles we’re developing increase the dose of energy absorbed by the tumor and make it possible to improve the local efficacy of the radiation therapy without increasing the dose received by the adjacent tissues. This is a true disruptive technology. Our technology makes...

Lees Meer
Jan 23 2013 | 8:36 AM

NYSE Euronext’s European markets Key figures on 31 December 2012

Companies listed on NYSE Euronext and NYSE Alternext raised € 84.3 billion in 2012. Total market capitalization on these markets was €2,148.2 billion on 31 December 2012. During the fourth quarter, four companies listed NYSE Euronext and NYSE Alternext.

Market capitalization on NYSE Euronext

Market capitalization on NYSE Alternext

Market capitalization on the Marché Libre

Number of Listed companies on NYSE Euronext’s markets


Lees Meer